Invitrogen: New Herceptin Candidate Dx Gives More Labs A Chance To Test
This article was originally published in The Gray Sheet
Executive Summary
Invitrogen's SPOT-Light HER2 test, PMA-approved by FDA July 8, will not be the first kit in the U.S. to help physicians decide if a breast cancer patient will benefit from Genentech's Herceptin therapy, but it will allow a host of new laboratories to perform the analysis, according to the firm